In survival mode, Exicure cuts to the bone — pausing all R&D and chopping headcount by 66%

The drastic restructuring that Exicure undertook at the end of last year couldn’t save the biotech after all.

In fact, Exicure — whose take on gene expression once drew the backing of Bill Gates and a slate of tech investors — is going for another round of layoffs, this time cutting to the bone with 66% of the remaining staffers being let go, while halting all R&D activities and looking to divest its entire pipeline.